HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on ADC Therapeutics (NYSE:ADCT) and maintained a price target of $12.
September 19, 2023 | 10:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ADC Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $12.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in ADC Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100